IBES
Live / Applied — New application — not yet assigned to an examiner (as of 26 Feb 2026)
What this means for you
Not registered yet, but its 26 Feb 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99672754
- Mark type
- Stylized text
- Filed
- 26 Feb 2026
- Attorney of record
- Joe McKinney Muncy
Goods and services
- Class 005 — Pharmaceuticals: Syringes filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Biological reagent for medical purposes; Opotherapy preparations; Protein preparations for medical purposes
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals; Custom manufacturing of biological tissue, blood, cell and genetic material; Custom biomanufacturing of pharmaceutical preparations
Owner
- Singulera Therapeutics Inc., Chicago, IL, US
Prosecution history
- 28 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 26 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 26 Feb 2026 — NEW APPLICATION ENTERED